Clinical Report: mpMRI Nomogram for Predicting HER2 Status in Breast Cancer

Overview

This study developed and validated a nomogram combining multiparametric MRI and clinicopathological variables to predict HER2 status in breast cancer patients. The nomogram demonstrated significant predictive accuracy, with AUC values indicating its potential as a noninvasive tool for guiding targeted therapy selection.

Background

HER2 expression is crucial for determining treatment options in breast cancer, influencing prognosis and therapeutic strategies. Traditional assessment methods, such as immunohistochemistry and fluorescence in situ hybridization, have limitations, including sampling errors and dynamic changes in HER2 status. There is a pressing need for reliable, noninvasive methods to evaluate HER2 expression longitudinally, particularly as new therapies targeting HER2-low expression emerge.

Data Highlights

Key Findings

• The nomogram integrates mpMRI parameters with clinicopathological factors for HER2 status prediction.
• Significant differences in CA125, Ki-67, ADC-min, and ME were observed among HER2 subgroups.
• The nomogram achieved AUCs of 0.762 and 0.738 for differentiating HER2-over/HER2-low from HER2-zero in training and validation datasets, respectively.
• It effectively differentiates between HER2-over and HER2-low subtypes, with AUCs of 0.719 and 0.772.
• This tool addresses the clinical need for noninvasive HER2 status assessment in breast cancer.

Clinical Implications

The mpMRI-based nomogram provides a promising noninvasive approach to predict HER2 status, potentially guiding therapy selection for breast cancer patients. Its integration into clinical practice may enhance the accuracy of treatment decisions, particularly in light of evolving therapeutic options for HER2-low expression.

Conclusion

The developed nomogram represents a significant advancement in noninvasive HER2 status prediction, offering a valuable tool for clinicians in the management of breast cancer. Further validation and integration into clinical workflows are warranted to optimize patient outcomes.

Related Resources & Content

1. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update | Journal of Clinical Oncology, 2022 -- Guideline Update
2. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer | FDA, 2025 -- FDA Approval
3. European Radiology — A Dual-Phase Nomogram: A Non-Invasive Resource to Aid Breast Radiologists in Clinical Decision-Making
4. European Radiology — Creation and assessment of a radiomics nomogram utilizing [18F]FDG PET/CT to forecast prognostic risks in patients with pretreatment diffuse large B cell lymphoma
5. Frontiers in Oncology — Development and validation of a multiparametric MRI-based radiomics nomogram for the tripartite discrimination of primary benign, primary malignant, and metastatic lumbar spinal tumors
6. Frontiers in Oncology — MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study
7. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update | Journal of Clinical Oncology
8. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer | FDA
9. Prediction of HER-2 expression status in breast cancer based on multi-parameter MRI intratumoral and peritumoral radiomics - ScienceDirect